Applied Biosciences Hires Former Pfizer Business Unit Chief Medical Officer as Chief Executive Officer
LOS ANGELES, May 07, 2019 (GLOBE NEWSWIRE) -- Applied BioSciences Corp. (OTCQB: APPB), a diversified cannabinoid-based therapeutics company focused on the medical, biopharmaceutical testing, consumer and veterinary health industries, announced today the appointment of Dr. Raymond W. Urbanski MD, PhD, the former business unit Chief Medical officer and senior director of oncology research and development with Pfizer Inc. (PFE), as its Chief Executive Officer.
Dr. Urbanski, will work closely with the Board of Directors, will set the vision and strategic direction of the company putting into place the organizational structure, processes and key hires necessary to continue the growth of Applied BioSciences. Dr. Urbanski will also oversee the development of key products in the Applied BioSciences’ product pipeline, including assets within the newly formed Applied BioPharma division which is focused on innovative cannabinoid therapies being developed to address the unmet medical needs of patients across multiple therapeutic areas.
Dr. Urbanski joins Applied BioSciences with an impressive list of accomplishments throughout his career ranging from academic research and private practice to his work and rise within the pharmaceutical industry. Dr. Urbanski spent eight years with Pfizer and held several positions within the company which included medical director of diversified products, senior medical director of breast cancer products, senior medical director of oncology clinical R&D, and eventually Vice President/Chief Medical Officer of the Established Products Business Unit. In addition to his roles with Pfizer, Dr. Urbanski served as Chief Medical Officer of Mylan Inc., Chief Medical Officer of MannKind Corp., and Senior Director of US Medical Affairs for Aventis.
He brings extensive experience in building highly effective and efficient organizations as well as experience in all phases of drug development across numerous therapeutic areas including hematology/oncology, rheumatology, neurology, cardiovascular medicine, and endocrinology/diabetes.
“The strengthening of our executive team is a key development at an exciting time for the company enhancing our future growth trajectory,” said Scott Stevens, Founder and Chairman of the Board, “Dr. Urbanski's big pharma and biotech expertise is well suited to develop the assets and relationships of Applied BioSciences and Applied BioPharma. He will be instrumental in helping to guide our existing assets and Scientific Advisory board to commercial success. We are excited to have him join our team.”
“Since my days in practice I have been a believer in the cannabinoids. I always knew that the cannabinoids could be useful agents for the treatment of a whole range of ailments and diseases. As the science has progressed and some barriers have come down this is the ideal time and environment to make these products and drugs available. Applied BioSciences is uniquely poised to lead these efforts. “commented Dr. Urbanski.
About Applied BioSciences Corp.
Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries. The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.
About Trace Analytics Inc.
Trace Analytics Inc. is a leading cannabis science and technology company with significant footprints in lab testing, research and development and licensing. Trace Analytics was started by a group of scientists who specialized in analytical chemistry, genetics and molecular biology. The focus of the team is to ensure compliance with public safety standards and end user safety. Trace Analytics is in the process of expanding throughout the United States, and globally. With the goal of helping the rest of the world adopt "best practices" in cannabis and hemp testing, the company also provides expert consulting services to legislators and regulators in many countries, states and municipalities around the world. For more information, please visit: http://traceanalytics.com
To be added to the Applied BioSciences email distribution list, please email email@example.com with APPB in the subject line.
Facebook @remedicbd & @HerbalPetMeds
Instagram @remedishop & @herbal_pet
Twitter @remedishop & @herbal_pet
Safe Harbor Statement
Except for historical information contained herein, statements in this release may be forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Applied BioSciences Corp. (the “Company”) or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company’s filings with the Securities and Exchange Commission. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as (i) the development and protection of our brands and other intellectual property, (ii) the need to raise capital to meet business requirements, (iii) significant fluctuations in marketing expenses, (iv) the ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of our products and services, (v) the Company’s ability to conduct the business if there are changes in laws, regulations, or government policies related to cannabis, (vi) management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and (vii) other information that may be detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Applied BioSciences Corp.
Released May 7, 2019